Immunopathogenesis and therapy of cutaneous T cell lymphoma

Kim, E. J.

doi:10.1172/jci200524826

Cited by 190 publications

(165 citation statements)

References 46 publications

(57 reference statements)

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…There is growing evidence, however, that patients with CTCL are immunocompromised, and the current research suggests a pivotal role for the tumor in undermining host immunity. Patients with CTCL have reduced numbers of circulating dendritic cells, CD8+ T cells, and CD56+ NK cells [3]. In addition, the T cells that remain appear to have reduced activity.…”

Section: Immunopathogenesis and Immunomodulatory Therapiesmentioning

confidence: 99%

“…In patients with a leukemic component, the frequency of cytotoxic cells that were recently activated is reduced, presumably demonstrating an impaired ability to mount a cell-mediated response to intercurrent infections [28]. Correspondingly, there are reduced levels of Th1-associated cytokines [3]. Furthermore, there is a profound loss of T-cell receptor complexity, with TCR V subtypes comparable to those found in HIV; this change probably impairs the host's ability to combat the spectrum of microbial diversity [29].…”

Section: Immunopathogenesis and Immunomodulatory Therapiesmentioning

confidence: 99%

“…Therapies that produce a complete response are associated with immune reconstitution. There is restoration in the numbers of effector cells and the levels of type I and type II interferons [3]. The effects of the tumor cell may be mediated by the cytokines they express.…”

Section: Immunopathogenesis and Immunomodulatory Therapiesmentioning

confidence: 99%

See 2 more Smart Citations

Cutaneous T-cell lymphoma: Biologic targets for therapy

Choi¹,

Foss

2007

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation. As the disease progresses, there appears to be an accumulation of genetic and epigenetic changes that may contribute to the aggressiveness of the disease. Furthermore, the persistence of tumor appears to require escape from cancer immunosurveillance. This process likely requires modulation of the host immune system and skewing of the immune cells away from a cytotoxic phenotype. Each of these steps in disease pathogenesis offers a potential object for targeted therapies. This article reviews the recent research into the design and use of targeted therapies for CTCL.

show abstract

Section: Immunopathogenesis and Immunomodulatory Therapiesmentioning

confidence: 99%

Section: Immunopathogenesis and Immunomodulatory Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous T-cell lymphoma: Biologic targets for therapy

Choi¹,

Foss

2007

Curr Hematol Malig Rep

View full text Add to dashboard Cite

show abstract

“…Möglicherweise lassen sich über den Einsatz von Cytosinphosphorotiolat-Guaninhaltigen Oligodeoxynukleotiden (CPG-ODNS) durch Bindung an Toll-like-Rezeptor 9 dendritische Zellen beeinflussen [14].…”

Section: Weitere Therapieoptionenunclassified

Kutane Lymphome

Stadler

2006

Hautarzt

View full text Add to dashboard Cite

Cutaneous lymphomas are a heterogeneous group of clonal proliferations of T and B lymphocytes with various clinical manifestations and prognosis. The new EORTC WHO classification of cutaneous T- and B-cell lymphomas provides a uniform nomenclature based on clinical, histologic, cytologic and molecular biological features. Accurate classification is a prerequisite for uniform therapeutic concepts. For office-based dermatologist, more than 50% of the therapies deal with classic forms of cutaneous T-cell lymphomas, type mycosis fungoides. In recent years the paradigm for the therapy of cutaneous T-cell lymphomas has changed. Since early aggressive treatment with cytostatic agents does not increase the response rate or overall survival, a commonly accepted stage-adapted therapy is recommended. In this review the current status of the therapy of cutaneous lymphoma is described in detail.

show abstract

“…Staging is based on the integration of cutaneous, lymph node, and visceral involvement (see Tables 1 and 2) [27]. The breadth of recently approved and emerging therapies for CTCL warrants detailed and accurate assessments of response to therapy [28][29][30][31][32][33][34][35][36][37][38][39][40].…”

mentioning

confidence: 99%

FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma

et al. 2008

View full text Add to dashboard Cite

This comprehensive case series illustrates the findings on 2-deoxy-2-[F-18]fluoro-D: -glucose (FDG) positron-emission tomography/computed tomography (PET/CT) of patients with varying stages of cutaneous T-cell lymphoma (CTCL). Patients were imaged with full-body scanning using a General Electric Discovery ST 16-slice PET/CT machine. Patients were assessed by PET/CT for cutaneous, nodal, and solid organ FDG uptake, indicative of highly metabolically active (i.e., putatively malignant cells) disease, and comparisons were made to CT data alone and to the physical examination. Several key observations strongly suggested that information afforded by PET/CT scan may be valuable. Various cutaneous lesions, from thin subtle plaques to thick tumors, were revealed and corresponded accurately to the cutaneous examination. In the case of subcutaneous lesions, PET/CT outperformed physical exam. CT also provided the depth/thickness of lesions. The differing levels of FDG uptake in enlarged nodes found within an individual patient as well as among different patients may potentially distinguish reactive from malignant adenopathy. Additionally, lymph nodes that did not meet staging size criteria (e.g., were not > 1 cm) revealed increased metabolic activity and, therefore, could be targeted for subsequent monitoring or biopsy. In addition, PET/CT identified visceral involvement in cases with advanced disease. In summary, PET/CT can provide physiologic and anatomic information on the wide diversity of external and internal lesions in CTCL and, therefore, may have great potential for improving the staging and monitoring of response to therapy of cutaneous, nodal, and visceral disease.

show abstract

Immunopathogenesis and therapy of cutaneous T cell lymphoma

Cited by 190 publications

References 46 publications

Cutaneous T-cell lymphoma: Biologic targets for therapy

Cutaneous T-cell lymphoma: Biologic targets for therapy

Kutane Lymphome

FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma

Contact Info

Product

Resources

About